Public Announcement of the Environmental Impact Assessment Report for the Generic Drug R&D Project of Beijing Haibu Pharmaceutical Technology Co., Ltd.

Beijing Haibu Pharmaceutical Technology Co., Ltd. was established in April 2005 and is a high-tech enterprise with "chemical drug research and development" as its core capability. The company's business mainly focuses on three sectors: (1) full-chain, multi-module R&D CRO services for chemical drugs (generic drugs, innovative drug CMC); (2) CRO technical services for raw materials and intermediates, customized R&D, related registration review, and domestic and international sales; (3) MAH licensed management services (raw material-related + CRO R&D services + CMO settlement services + registration services + full-process quality management services).
Since its establishment, Haibu has developed products covering multiple therapeutic areas including anti-tumor, mental and neurological disorders, cardiovascular diseases, digestive diseases, respiratory diseases, etc., completing over 100 technology transfers to domestic pharmaceutical companies...